Dr. Goettig: remember to clean your phone when working in healthcare settings @esgarsociety.bsky.social @escmid.bsky.social @taescmid.bsky.social

Dr. Naas: lateral flow looking for carbapenemases can be directly performed from positive blood cultures Published in @jac-amr.bsky.social @esgarsociety.bsky.social

Lateral flow assays work well to detect main types of carbapenemases. Rapid and affordable without requiring a cold chain. @esgarsociety.bsky.social

Dr. Thierry Naas now presents on novel ID diagnostics in carbapemase detection. AI-guided interpretation may be helpful to predict carbapenemases. @esgarsociety.bsky.social @escmid.bsky.social

Dr Karakosta now presents on outcomes of patients screen positive for carriage of CRO, VRE and/or C. Diff in Greece. High carriage rates 20% CRO (k. Pneumo, crab, psa) 35% VRE 10% c. Diff RF as expected (healthcare + abx) unadjusted OR of 9 for subsequent CRE BSI @esgarsociety.bsky.social

Very high carbapenem resistance rates (>85%!) in K. pneumoniae from nosocomial BSI with a rise in NDM between 2020-2025 in a Greek hospital. Presented at ESGARS meeting in Athens @escmid.bsky.social @esgarsociety.bsky.social

Pleased to share our article is published (in the pretty format) re: RSV vaccination in an ambulatory clinic. Led by our amazing PGY2 AmbCare resident Amy Liu during a 2 week period bc ... she was just too damned good at her rotation and we needed to fill the time somehow 😂 doi.org/10.1017/ash....

🆕💥🟢Resistance to novel β-lactam/β-lactamase inhibitors in CRPA — snapshot from a multinational study: • 35 hospitals • 9 countries • 800 isolates Susceptibility: 🔺C/T: 69% 🔺 CZA: 67% 🔺imipenem-relebactam: 33% 😲 #idsky journals.asm.org/doi/10.1128/aa…journals.asm.org/doi/10.1128/...25

Dr. Elda Righi (Associate Editor for @jac-amr.bsky.social) now chairing the last session of the day. Invited papers supported by JAC and JAC-AMR @bsacandjac.bsky.social Should be great session covering patient perspectives, the UK antibiotic registry, big data, and more

Dr Netta Tyler now presents on novel antifungals. @bsacandjac.bsky.social Nice overview from 2024 in CMR here: journals.asm.org/doi/10.1128/...

Authors (@joseph-ladines-lim.bsky.social) provide ongoing guidance on ID care to immigrant, refugee, and asylee populations, as well as others disadvantaged, accounting for policy changes that have occurred under the current federal administration in the past year. doi.org/10.1017/ash....

Dr. Denning now presents on global burden of fungal disease: Epidemiology, trends & emerging threats. Talking about azole resistance in Aspergillus. Very geographically variable and linked to non-clinical antifungal use eg agriculture. For recent review global epi: academic.oup.com/jacamr/artic...

Dr. Donnelly of JAC fame describes common perception of reviewers in medical publishing. @bsacandjac.bsky.social #IDsky

Dr Peter Donnelly now giving the Garrod lecture. Such an impressive career @bsacandjac.bsky.social

Laura Ahearn, RN now speaking on the essential role of RN in antimicrobial stewardship. @bsacandjac.bsky.social Important message that without appropriate diagnosis, good stewardship is impossible

Dr. Cooper: pilot project on delinkage with caz-avi and cefiderocol. Value in QALYs higher for cefiderocol (16,200) vs caz-avi (8,880) in a model of 20 years. Details on www.nice.org.uk @bsacandjac.bsky.social

Dr. Sophie Cooper from the UK National Institute of Health and Care Excellence (NICE). Speaking on de-linkage for antibiotics. In UK subscription model: pay for antibiotics regardless of volume used, based on perceived society benefits (Prof Rex: abx as fire extinguishers of medicine)

President Andrew Seaton opens the spring conference for BSAC. >10,000 members currently #IDsky bsac.org.uk/membership/

bsac-conference.com Looking forward to BSAC Spring conference Dr. Peter Donnelly giving the Garrod lecture tomorrow👍

Invasive Fusariosis: A Retrospective Case Series Evaluating In Vitro Minimum Inhibitory Concentrations and Clinical Response @annwoolleymd.bsky.social &co at Brigham & Women's, Dana Farber No association b/w MICs & clinical outcomes #ThingsWeDoForNoReason #IDSky academic.oup.com/ofid/advance...

Great to have Dr Jay Fishman from Harvard coming to talk to us about transplant ID at UNC

For decades, the US federal government has been one of the foremost producers of information in the world. But over the past year, the Trump administration has been altering and removing decades’ worth of datasets, with enormous impact on all aspects of life. 🧵

Just the latest example of poverty is the real disease An RCT in Tanzania showed that improved housing with better ventilation, vector control and sanitation led to fewer cases of malaria, diarrhea and respiratory infections in children. www.science.org/content/arti...

It's #WorldImmunizationWeek and the theme is "For every generation, vaccines work" Vaccines are not just for children, the elderly or the immunosuppressed but are important throughout the course of all our lives allowing us to prevent illness and lead healthier lives. #VaccinesWork #IDSky #Vaccines

Next up: Dr Lauren Saint from UNC discusses a case of joint swelling in knee, finger, toe. Skin lesions and painful eye with blurry vision and increased eye pressure and uveitis leading to loss of vision in eye. US travel only. Transports live pigs as truck driver.

Next case in clinical grand rounds is quant-positive patient from London with oral ulcers, thalamic lesion, CSF pleiocytosis, eosinophilia, and travel history #ESCMIDGlobal2026

My first session on the last day of #ESCMIDGlobal2026 is Bird flu is no longer just for birds: from strategic planning to public health readiness. The first speaker is Ben Cowling with What drives pandemic risk? Virus, population and policy influencing influenza H1N1 spread

As always, Clinical Grand Rounds led expertly by Dr Robert Read, delivers Great case of secondary syphilis with disseminated spirochetes seen in various tissues #ESCMIDGlobal2026

Waldorf and Statler enjoying the “trial run to non-inferiority” session at ESCMID Global 2026, remembering the times of superiority. @cmicomms.bsky.social @angelahuttner.bsky.social @absteward.bsky.social

“This Year in Public Health” at #ESCMIDGlobal2026: 💉 Vaccines can stop cholera—but timing is everything ⏳ Doses arriving 2–4 weeks late = outbreaks already accelerating 🚑 8M vaccines delivered, massive mobilization on the ground We have the tools. The gap is speed, access, and delivery.

“This Year in Public Health” at #ESCMIDGlobal2026: ⚔️ War accelerates AMR 🏥 Strained systems + disrupted surveillance 🦠 Resistance spreads across care networks A hidden consequence of conflict—and a growing threat.

“This Year in Public Health” at #ESCMIDGlobal2026: 💊 Cutting unnecessary antibiotics isn’t just good medicine—it saves money 📉 Stewardship programs reduce overprescribing 💰 Lower drug costs, fewer adverse events, less AMR burden Better prescribing = better outcomes + real savings

My first #ESCMIDGlobal2026 session on Monday is Interconnected microbiomes and resistomes across One Health. The first speaker is Amy Mathers with Hospital microbiomes as hotspots for emerging resistance: surveillance-to-intervention

“This Year in Public Health” at #ESCMIDGlobal2026: 📊 Global DALYs tell the story across the lifespan 👶 Early life still shaped by infectious diseases 🧓 Later life dominated by NCDs (CV disease, cancer, neuro) ⚠️ Injuries and mental health contribute across ages The burden is shifting

Dr Kurt Hanevik starts his overview of year in public health with a Lancet report on global burden of disease. Communicable diseases dominate in early years with other causes such as cancer more important in older people. #ESCMIDGlobal2026 www.thelancet.com/journals/lan...

Normal urine is not sterile! Urine microbiome being introduced by @nicoledenisco.bsky.social #ESCMIDGlobal2026 #UTISky

A year in public health about to start in ICM14. Should be a good one ⭐️ #ESCMIDGlobal2026

Presented at #ESCMIDGlobal2026: 📊 Research Summary: In patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day outcomes compared with standard testing, although it supported faster antibiotic adjustments. ja.ma/4cpmioY

🙌 🚪 Great talk and I’m feeling very encouraged and way more informed about DOOR from the talks at #ESCMIDglobal2026 …Advocacy to use this tool is loud and clear!! @josemolinagb.bsky.social @escmid.bsky.social @absteward.bsky.social @krutikakuppalli.bsky.social @drneilstone.bsky.social

Dr Kontoyiannis now giving key note in ICM14 Starts with fascinating history of IFI in leukemia #ESCMIDGlobal2026

Looking forward to seeing you at this exciting ESCMID Late-breaking session on Sunday 👇👇 @escmid.bsky.social @cmijournal.bsky.social @cmicomms.bsky.social @unmc-id.bsky.social #IDSky #MedSky #PCCSky #ICUSky #EMIMCC #Ansky #EMSky #AMSSky #TxID #meded #Pharmsky #Pharmed #RXSky #MicroSky #ClinMicro

Day 3 of #escmidglobal2026 here in Munich 🇩🇪 Bugs on the menu..food borne pathogen Dr Megan Carey on XDR typhoid which continues to spread

Check out the IDSA booth B2G03 They have chocolate #ESCMIDGlobal2026 @idweek.bsky.social @idsainfo.bsky.social

Check out the IDSA booth B2G03 They have chocolate @idweek.bsky.social @idsainfo.bsky.social

Difficult to know what to say about tebipenem for pyelonephritis. Small sample sizes but tebipenem looks worrying for use in pyelonephritis with bacteraemia - problem is you never know who does / does not have bacteraemia (and we probably miss many) #ESCMIDGlobal2026

“Year in Infection Control” papers #ESCMIDGlobal2026 talk by Nico Mutters Papers highlighted included @jamanetworkopen.com study jamanetwork.com/journals/jam...

Now up: a change of pace looking at how new antibacterials should be evaluated. Conducting stand-alone two-arm trials very time and money consuming. Dr. Melissa Hardy proposes GNR research should take a page out of SNAP playbook and conduct platform trials instead. #ESCMIDGlobal2026

Wonderful talk by Kalis Marimuthu, Singapore, on Toilets: flushing and spread of AMR pathogens #ESCMIDGlobal2026

👏👏 Incredible job covering so many key points, an on the mark lecture by @IDdocAkshatha here at #ESCMIDglobal2026 @ESCMID …She asks the audience to become a DOL, talks risks vs benefits, and a changing landscape where silence is no longer neutral

Cefepime-enmetazobactam up now The antibiotic we never knew we needed(?) Subgroup analyses of 2022 RCT in which it was superior to pip-tazo for cUTI This was maintained in ESBL infection subgroup (relatively small numbers) jamanetwork.com/journals/jam... #ESCMIDGlobal2026